Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/161200

Lähdeviite

Boije af Gennäs , G , Talman , V , Yli-Kauhaluoma , J , Tuominen , R K & Ekokoski , E 2011 , ' Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates ' , Current Topics in Medicinal Chemistry , vol. 11 , no. 11 , pp. 1370-1392 .

Julkaisun nimi: Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Tekijä: Boije af Gennäs, Gustav; Talman, Virpi; Yli-Kauhaluoma, Jari; Tuominen, Raimo K.; Ekokoski, Elina
Tekijän organisaatio: Faculty of Pharmacy
Division of Pharmaceutical Chemistry and Technology
Division of Pharmacology and Pharmacotherapy
Päiväys: 2011
Kieli: eng
Sivumäärä: 23
Kuuluu julkaisusarjaan: Current Topics in Medicinal Chemistry
ISSN: 1568-0266
URI: http://hdl.handle.net/10138/161200
Tiivistelmä: The second messenger diacylglycerol (DAG) plays a central role in the signal transduction of G-protein coupled receptors and receptor tyrosine kinases by binding to C1 domain of effector proteins. C1 domain was first identified in protein kinase C (PKC) which comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders. Drug discovery concerning C1 domains has exploited both natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds.
Avainsanat: Protein kinase C
C1 domain
drug discovery
cancer
Alzheimer's disease
bryostatins
ingenol-3-angelate
DAG-lactones
PROTEIN-KINASE-C
CONFORMATIONALLY CONSTRAINED ANALOGS
CHRONIC LYMPHOCYTIC-LEUKEMIA
ACTIVATOR-BINDING DOMAIN
PHORBOL ESTER RECEPTOR
CELLS IN-VITRO
NF-KAPPA-B
NEURONAL ELAV PROTEINS
LACTONES DAG-LACTONES
PROSTATE-CANCER CELLS
317 Pharmacy
Vertaisarvioitu: Kyllä
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: acceptedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Boije_et_al_2011_CurrTopMedChem_POSTPRINT.pdf 1.359MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot